In human prostate cancer, ERβ signaling appears to inhibit cell survival of TMPRSS2–ERG tumors, which usually have a more aggressive clinical phenotype18; ERβ is downregulated in some tumors4,7,19,20; and a correlation has been observed between partial loss of ERβ and castration resistance2. This evidence concerns the gene ESR2 and prostate cancer.